Long-Term Follow-Up for Gene-Modified T Cell Treatment

We are monitoring patients treated with gene-modified T cells to assess any delayed side effects and the long-term effectiveness of the treatment. This study also looks at the health of younger patients who received this therapy.

>2 years 11-15 visits Efficacy phase (II)Confirmation phase (III)Cost Reimbursement Partially Remote Investigational Medicines InjectionHematologyInternal MedicineOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Idecabtagene Vicleucel

Idecabtagene vicleucel is a cellular immunotherapy that uses a patient's own modified immune cells to target advanced multiple myeloma.

Lisocabtagene Maraleucel

Lisocabtagene maraleucel is a personalized CAR T-cell therapy that uses a patient's own immune cells engineered to target and kill certain B-cell cancers.

What experimental substances are being tested?

Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.

Gprc5d-Targeted Car T

Cd19-Targeted Nex-T Car T

Dual Targeting BcmAxGprc5d Car T

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...

Ordensklinikum Linz GmbH

Elisabethinen I.Internal Depart., Hematology w. stem cell transpl., haemostaseology & med. oncology

Linz, Austria

SCRI CCCIT Ges.m.b.H.

Klinik für Innere Medizin III PMU

Salzburg, Austria

Hanusch Krankenhaus Der Wiener Gebietskrankenkasse

3.Medizinische Abteilung – Abteilung für Hämatologie & Onkologie

Vienna, Austria

Sponsor: Celgene Corp.

Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.